Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.

You may also be interested in...



Another Disappointment For Pfizer; PAH Drug Withdrawn

Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.

Another Disappointment For Pfizer; PAH Drug Withdrawn

Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.

Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA

Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.

Related Content

Topics

UsernamePublicRestriction

Register

PS066189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel